ascorbic-acid and Dyspnea

Topics: Ascorbic Acid; Cyanosis; Daucus carota; Diagnosis, Differential; Dyspnea; Emergency Treatment; Humans; Infant; Male; Methemoglobinemia; Nitrites; Severity of Illness Index; Shock, Septic; Tunisia

There is limited evidence regarding early treatment of novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection to mitigate symptom progression.. To examine whether high-dose zinc and/or high-dose ascorbic acid reduce the severity or duration of symptoms compared with usual care among ambulatory patients with SARS-CoV-2 infection.. This multicenter, single health system randomized clinical factorial open-label trial enrolled 214 adult patients with a diagnosis of SARS-CoV-2 infection confirmed with a polymerase chain reaction assay who received outpatient care in sites in Ohio and Florida. The trial was conducted from April 27, 2020, to October 14, 2020.. Patients were randomized in a 1:1:1:1 allocation ratio to receive either 10 days of zinc gluconate (50 mg), ascorbic acid (8000 mg), both agents, or standard of care.. The primary end point was the number of days required to reach a 50% reduction in symptoms, including severity of fever, cough, shortness of breath, and fatigue (rated on a 4-point scale for each symptom). Secondary end points included days required to reach a total symptom severity score of 0, cumulative severity score at day 5, hospitalizations, deaths, adjunctive prescribed medications, and adverse effects of the study supplements.. A total of 214 patients were randomized, with a mean (SD) age of 45.2 (14.6) years and 132 (61.7%) women. The study was stopped for a low conditional power for benefit with no significant difference among the 4 groups for the primary end point. Patients who received usual care without supplementation achieved a 50% reduction in symptoms at a mean (SD) of 6.7 (4.4) days compared with 5.5 (3.7) days for the ascorbic acid group, 5.9 (4.9) days for the zinc gluconate group, and 5.5 (3.4) days for the group receiving both (overall P = .45). There was no significant difference in secondary outcomes among the treatment groups.. In this randomized clinical trial of ambulatory patients diagnosed with SARS-CoV-2 infection, treatment with high-dose zinc gluconate, ascorbic acid, or a combination of the 2 supplements did not significantly decrease the duration of symptoms compared with standard of care.. ClinicalTrials.gov Identifier: NCT04342728.

Topics: Adult; Ambulatory Care; Antioxidants; Ascorbic Acid; Cough; COVID-19; COVID-19 Drug Treatment; Dietary Supplements; Dyspnea; Fatigue; Female; Fever; Gluconates; Humans; Male; Middle Aged; SARS-CoV-2; Severity of Illness Index; Standard of Care; Trace Elements; Treatment Outcome; Zinc

A female patient presented with exertional dyspnea, myalgia, a petechial rash of the lower extremities and pronounced gingivitis. The biochemical test results showed the presence of anemia. The patient had a known eating disorder and on questioning about eating habits admitted that she did not eat any fruit or vegetables. This led to the suspicion of a vitamin C deficiency, which was confirmed by high-pressure liquid chromatography. The patient was subsequently treated with 1000 mg ascorbic acid daily for 1 month whereby the clinical symptoms and anemia improved within a few weeks.

Topics: Ascorbic Acid; Ascorbic Acid Deficiency; Dyspnea; Female; Gingivitis; Humans; Lower Extremity; Middle Aged; Myalgia; Purpura

Topics: Aged; Ascorbic Acid; Cyanosis; Dermatitis Herpetiformis; Dyspnea; Female; Humans; Oxygen; Sulfones

Scurvy occurred in an elderly man with fatigue, dyspnea on exertion, and extensive ecchymoses and brawny edema of the legs. Platelet count, prothrombin time, and partial thromboplastin time were normal, but serum ascorbic acid level was very low. Other signs considered to be classic and almost pathognomonic for were absent: bleeding gums, hyperkeratotic follicles, coiled hairs, and perifollicular hemorrhages. Reliance on these well-known features of scurvy may obscure or delay diagnosis of an easily cured disorder Severe scurvy is most commonly suggested by tenderness, extensive ecchymoses, and brawny edema of the lower extremities.

Topics: Aged; Ascorbic Acid; Diet; Dyspnea; Ecchymosis; Edema; Fatigue; Humans; Male; Mouth, Edentulous; Scurvy

Three cases are described, 2 of Hodgkin's disease and a further case of bronchial carcinoma, where high dosage ascorbic acid treatment appeared to be associated with the development of potentially dangerous symptoms. It is suggested that mega ascorbic acid therapy should be given with caution in malignant disease, with a slow build-up over several days to high levels of dosage.

Topics: Adult; Aged; Animals; Antineoplastic Agents; Ascorbic Acid; Bronchial Neoplasms; Carcinoma, Small Cell; Dyspnea; Fever; Hodgkin Disease; Humans; Lung Neoplasms; Male; Neoplasms; Orthomolecular Therapy

Topics: Ascorbic Acid; Child, Preschool; Cyanosis; Dapsone; Dyspnea; Female; Heart Rate; Hemoglobins; Humans; Hyperkinesis; Infant; Leukocyte Count; Male; Methemoglobinemia; Methylene Blue; Vomiting